BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2026	FY 2024	FY 2023	FY 2022
Period Ending	Apr 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Market Cap	5	10	5	9	165
Market Cap Growth	21.32%	89.79%	-46.27%	-94.33%	-
Enterprise Value	1.34	5.63	0.81	3.53	162.95
Last Close Price	2.18	3.95	2.80	5.30	114.00
PE Ratio	-	-2.46	-3.12	-31.93	-247.83
PS Ratio	0.69	1.29	0.53	0.96	15.10
PB Ratio	0.61	1.11	0.60	0.97	24.76
P/TBV Ratio	0.47	0.85	0.60	0.79	24.65
P/FCF Ratio	-	-5.09	-2.17	-4.75	331.62
P/OCF Ratio	-	-5.19	-2.40	-5.14	299.07
EV/Sales Ratio	0.18	0.76	0.09	0.36	14.91
EV/EBITDA Ratio	-	-2.01	-0.57	-1.42	-877.24
EV/EBIT Ratio	-	-1.90	-0.52	-1.36	-559.64
EV/FCF Ratio	-	-3.00	-0.35	-1.79	327.45
Debt / Equity Ratio	0.01	0.01	0.02	0.01	0.01
Debt / EBITDA Ratio	-0.06	-0.06	-0.15	-0.05	-0.31
Debt / FCF Ratio	-0.09	-0.09	-0.09	-0.07	0.11
Net Debt / Equity Ratio	-0.45	-0.45	-0.50	-0.60	-0.31
Net Debt / EBITDA Ratio	1.38	1.38	2.93	2.33	11.10
Net Debt / FCF Ratio	2.06	2.06	1.80	2.94	-4.14
Asset Turnover	0.75	0.75	0.87	0.97	1.25
Inventory Turnover	6.14	6.14	6.51	7.98	9.89
Quick Ratio	8.88	8.88	3.05	4.20	2.50
Current Ratio	10.46	10.46	3.81	4.93	3.00
Return on Equity (ROE)	-35.24%	-35.24%	-17.78%	-32.21%	-5.34%
Return on Assets (ROA)	-30.12%	-30.12%	-14.45%	-25.97%	-3.91%
Return on Invested Capital (ROIC)	-65.32%	-65.32%	-38.67%	-61.21%	-7.33%
Return on Capital Employed (ROCE)	-34.45%	-34.45%	-17.24%	-31.43%	-4.32%
Earnings Yield	-57.92%	-40.68%	-32.04%	-3.13%	-0.40%
FCF Yield	-36.39%	-19.64%	-46.12%	-21.06%	0.30%
Buyback Yield / Dilution	-4.20%	-4.20%	-23.66%	0.00%	-
Total Shareholder Return	-4.20%	-4.20%	-23.66%	0.00%	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q